Innate Pharma (IPH) Company presentation summary

Strategic focus and portfolio overview

• Specializes in oncology with a focus on three high-value clinical assets: lacutamab, monalizumab, and IPH4502.

• Emphasizes in-house expertise in antibody therapeutics and a proprietary ADC pipeline.

• Organization is reshaped for agile execution and impact in targeted cancer indications.

Lacutamab: Clinical progress and commercial potential

• Lacutamab targets KIR3DL2 in CTCL and PTCL, addressing high unmet medical need, especially in Sézary syndrome and mycosis fungoides.

• Phase 2 TELLOMAK showed durable responses and favorable tolerability in heavily pre-treated patients.

• Strategic partnership with Sobi includes $75M upfront, up to $505M in milestones, and tiered royalties; Sobi to commercialize globally upon approval.

• Pathway to accelerated approval in SS, with Phase 3 TELLOMAK-3 trial set for H2 2026, pending transaction closure.

• Peak year sales potential estimated at over $500M, with significant market expansion opportunities in CTCL.

Monalizumab: Partnership and late-stage development

• Monalizumab, co-developed with AstraZeneca, is in Phase 3 PACIFIC-9 for NSCLC, with enrollment completed and data expected H2 2026.

• Phase 2 COAST trial showed improved progression-free survival when combined with durvalumab.

• AstraZeneca partnership includes $450M received, up to $825M in milestones, 50% profit share in Europe, and double-digit royalties elsewhere.